<?xml version="1.0" encoding="UTF-8"?>
<p>Interferons (IFNs) are induced upon coronavirus infections (Park &amp; Iwasaki, 
 <xref rid="embj2020106057-bib-0025" ref-type="ref">2020</xref>). IFNs are signaling molecules of the innate immune system that confer a first line of antiviral defense (Liu 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0019" ref-type="ref">2013</xref>). Upon sensing of molecular patterns associated with viral infections, IFN pathways become activated, engendering further activation of hundreds of interferon‐stimulated genes (ISGs) that counteract many steps in the virus life cycle (Liu 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0019" ref-type="ref">2013</xref>). Human type I IFNs including IFN‐α and IFN‐β function through the ubiquitously expressed type I interferon receptor (IFNAR), while type III IFNs, IFN‐λ, bind to the epithelia‐restricted type III interferon receptor (IFNLR; de Weerd &amp; Nguyen, 
 <xref rid="embj2020106057-bib-0031" ref-type="ref">2012</xref>). 
 <italic>In vitro</italic> and clinical studies have shown that SARS‐CoV‐2 is sensitive to type I IFNs and that type I IFN treatment could be a promising therapeutic strategy for COVID‐19 (Mantlo 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0021" ref-type="ref">2020</xref>; preprint: Meng 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0022" ref-type="ref">2020</xref>; preprint: Zhou 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0037" ref-type="ref">2020</xref>).
</p>
